This review evaluated the efficacy and safety of topical rubefacients in the treatment of acute and chronic pain. The authors concluded that topically applied rubefacient may be efficacious in the treatment of acute pain. However, they acknowledge that estimates for the efficacy of rubefacients are unreliable, owing to the lack of good clinical trials.
Results of the review
Twelve studies (n=862) were included in the review.
The quality scores ranged from 2 to 4 out of a possible 5. On the 16-point validity assessment, the scores ranged from 5 to 14.
Efficacy.
Based on 182 patients in 3 studies, rubefacient resulted in a statistically significant improvement in acute pain compared with placebo (RR 3.6, 95% CI: 2.4, 5.6, P<0.00001) and the corresponding NNT was 2.1 (95% CI: 1.7, 2.8). There was evidence of statistical heterogeneity (P<0.00001; I2=91.9%).
Based on 455 patients in 6 studies, rubefacient resulted in a statistically significant improvement in chronic pain compared with placebo (RR 1.5, 95% CI: 1.3, 1.9, P<0.0001) and the corresponding NNT was 5.3 (95% CI: 3.6, 10.2). There was no evidence of statistical heterogeneity (P=0.15; I2=38.3%). Subgroup analyses of studies of chronic pain showed no significant effect of outcome measured (P=0.76) or type of placebo (P=0.58). However, the analgesic effect was lower in studies with higher validity scores (P=0.009).
Adverse events.
There was no significant difference in the number of local adverse events between rubefacient and placebo. The quality of the reporting was poor and insufficient data were provided for statistical analysis. No withdrawals related to adverse events were reported.
